

What is claimed is:

1. A polymeric drug delivery composition comprising polyphosphazene based polymers and at least one therapeutic agent.
- 5 2. The composition of claim 1, wherein said polyphosphazene based polymers comprise nanoparticles.
3. The composition of claim 2, wherein said polyphosphazene based nanoparticles range in
10 size from 5 nm to 500 nm.
4. The composition of claim 3, wherein said nanoparticles are concentrated in size at about 100 nm or less.
- 15 5. The composition of claim 1, wherein said therapeutic agent comprises a chemotherapeutic agent.
6. The composition of claim 5, wherein said chemotherapeutic agent comprises Paclitaxel.
- 20 7. The composition of claim 6, wherein said Paclitaxel is provided at 540-700 mg/m².
8. The composition of claim 7, wherein said Paclitaxel is provided at 405-525 mg/m².
9. The composition of claim 8, wherein said Paclitaxel is provided at 270-350 mg/m².
- 25 10. The composition of claim 9, wherein said Paclitaxel is provided at 135-175 mg/m².
11. The composition of claim 6, wherein said Paclitaxel is provided at 1250-1875 mg/m².
- 30 12. The composition of claim 5, wherein said chemotherapeutic agent is loaded at a ratio of about 4% to about 10% of said polyphosphazene based polymers.
13. The composition of claim 12, wherein said chemotherapeutic agent is loaded at a ratio of about 6% to about 8% of said polyphosphazene based polymers.

14. The composition of claim 13, wherein said chemotherapeutic agent is loaded to about 7% of said polyphosphazene based polymers.
- 5 15. The composition of claim 14, wherein said chemotherapeutic agent comprises Paclitaxel.
16. A method of using the composition of claim 5 to treat or ameliorate a disease in a subject.
17. The method of claim 16, wherein said disease comprises cancer or a neoproliferative
10 disease.
18. The method of claim 16, wherein said subject is a mammal.
19. The method of claim 18, wherein said mammal is a human.
- 15 20. The composition of claim 5 for use as a medicament.
21. The composition of claim 5 for use in the treatment of a disease.
- 20 22. The use of the composition of claim 21, wherein said disease comprises cancer or a neoproliferative disease.
23. The composition of claim 5, further comprising a kit comprising instructions for
administration of said composition to a subject.
- 25 24. The kit of claim 23, wherein said subject comprises a human.
- 30